CSL

Incorporated in 1916, CSL has established its headquarters in Parkville, Melbourne, Victoria, Australia. The company's business is segmented into two main categories: CSL Behring and Seqirus. CSL Behring is renowned for providing innovative treatments for immunodeficiencies, bleeding disorders, and other rare and serious medical conditions. Seqirus, on the other hand, holds a prominent position as one of the world's largest influenza vaccine companies, focusing also on antivenom treatments. The company's success is marked by the development and distribution of several key brands. Among these, Hizentra and Privigen are notable for their use in immunodeficiency treatments, while Hemate-P, Berinert, Idelvion, Afstyla, and Haegarda have become essential in the management of bleeding disorders. Moreover, Seqirus contributes significantly to public health with its influenza vaccine brands Afluria, Fluad, and Flucelvax. CSL has identified the United States, Germany, China, the United Kingdom, and Australia as the most important countries for sales of its products and services. However, CSL's offerings are available globally, as the company operates in various other international markets, providing healthcare solutions around the world. (Powered by AI)